Biomanufacturing Excellence Act: Strengthening ...

By João L. Carapinha

December 3, 2025

Launching the Biomanufacturing Excellence Act of 2025 The Biomanufacturing Excellence Act of 2025, introduced as
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications
Biosimilars Market Trends 2025: Understanding Erosion and Growth
Transforming Cancer Treatment: Implications of Subcutaneous Pembrolizumab App...
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
Innovative Strategies of MoonLake Immunotherapeutics HS in Targeting Inflamma...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...